The drugmaker’s titanic plunge was catalyzed by the termination of itslicense and collaboration agreement with Sanofi for inhaled insulin product Afrezza last April. Sanofi decided to end the partnership with MannKind because of Afrezza’s unexpectedly weak launch that produced a grand total of $5.2 million in net sales during the first nine months of 2015.